The use of cyclosporin A has been associated with several side-effects, including neurotoxicity. The mechanism of toxicity is not well known. We report two patients treated with cyclosporin A who developed lesions in the cerebral white matter associated with abnormally elevated cerebral blood flow velocities on transcranial doppler ultrasound and abnormal vascular appearance on magnetic resonance angiography. Bone Marrow Transplantation (2000) 26, 801-804. Keywords: cyclosporin A; toxicity; vasospasm; transcranial doppler ultrasound; magnetic resonance imaging; magnetic resonance angiography Cyclosporin A is an immunosuppressive agent used to prevent graft-versus-host disease (GVHD), to promote engraftment in transplantation and for treatment of multiple auto-immune diseases.
Cyclosporin A is an immunosuppressive agent used to prevent graft-versus-host disease (GVHD), to promote engraftment in transplantation and for treatment of multiple auto-immune diseases. [1] [2] [3] It has been associated with several side-effects, including nephrotoxicity, hepatotoxicity and hypertension. 1 Neurotoxicity has been a recognized complication of the use of cyclosporin A in bone marrow and organ transplantation. Clinical manifestations include seizures, cortical blindness, altered mental status and quadriparesis. 1 CNS lesions caused by cyclosporin A have been localized mainly in watershed zones in the parietal and occipital lobes, and less frequently in the frontoparietal and inferotemporo-occipital junctions, or cerebellum. These lesions are identical to those seen due to cerebral hypoperfusion secondary to cardiac arrest, malignant hypertension or pre-eclampsia/eclampsia. They consist of white matter hypo-attenuation on computed tomography (CT) and hyperintensity on T 2 weighted images on magnetic resonance imaging (MRI). 4 The mechanism of cyclosporin A neurotoxicity is not well known. However the distribution of the lesions suggests a vascular process. We report two patients treated with cyclosporin A in whom we demonstrated abnormally high cerebral blood flow velocities on transcranial Doppler ultrasound, as well as abnormal vascular appearance on magnetic resonance angiography (MRA).
Case reports

Case 1
A 34-year-old Caucasian woman with myelodysplastic syndrome underwent cord blood transplantation 5 days following treatment with busulfan, mephalan and antithymocyte globulin. She was started on cyclosporin A for GVHD prophylaxis 2 days prior to transplantation at a daily dose of 200 mg i.v. She was also started on i.v. methylprednisolone on the day of the transplant. Immediately following bone marrow transplantation, the patient developed a severe occipital headache. On day 5, she developed acute-onset left-sided weakness and blurred vision in the right eye. Later that day, she developed confusion, incomprehensible speech, and seizure activity of the left side of the body.
Physical examination revealed markedly increased tone in the left side with profound weakness, diffuse hyperreflexia and a left Babinski sign. Visual acuity testing using the Snellen's near card showed vision of 20/25 in both eyes. No visual field defects were detected. The patient had an increase in systolic blood pressure (BP) from a baseline of 100 to 120 mm Hg to 150 mm Hg on the day of transplantation. Following that, she had a systolic BP ranging between 140 to 160 mm Hg and an average diastolic BP of 70 to 80 mm Hg.
MRI of the brain showed a cortical infarct in the right precentral gyrus and bi-occipital white matter hyperintensities on T 2 -weighted images. MRA showed diffusely small intracranial arteries ( Figure 1 ). She had neutropenia, anemia and thrombocytopenia. The blood smear did not show schistocytes and serum lactate dehydrogenase level was normal. Cyclosporin A level was 279 ng/ml (therapeutic range: 100-300 ng/ml). Cerebrospinal fluid examination revealed 465 red blood cells, no nucleated cells, glucose 71 mg/dl, protein 53 mg/dl, and culture was negative for bacteria and fungi.
Transcranial Doppler (TCD) ultrasound showed elevated velocities in several vessels particularly both middle cerebral arteries, left anterior cerebral artery and right posterior cerebral artery (Table 1) . Cyclosporin A was discontinued, and the patient was placed on FK506 for GVHD prophylaxis, at a dose of 0.025 mg/kg/day. Follow-up TCDs Bone Marrow Transplantation Approximately 4 weeks following the first neurologic event, she developed a severe headache without additional Table 1 Mean intracranial blood flow velocities by transcranial doppler ultrasounds in case 1 (cm/s) 6  126  131  97  114  112  90  7  124  116  41  112  42  71  10  136  102  97  121  66  64  12  147  148  97  119  78  52  23  128  129  85  112  52  42  38  88  83  66  59  31 neurologic deficits. MRI of the brain revealed a new enhancing lesion in the right frontal lobe, as well as in the right posterior parieto-occipital lobe. Hemorrhagic infarction was demonstrated in the area of the previous right precentral lesion. There was resolution of the bi-occipital white matter T 2 -hyperintensities ( Figure 2 ). The FK506 level was 13.5 ng/ml (therapeutic range: 10-25 ng/ml). This was stopped for 1 day and restarted at a lower dose of 0.017 mg/kg/day. A right shoulder skin lesion was biopsied and its culture grew Aspergillus terreus. The patient's course was later complicated by renal failure and failure of bone marrow engraftment. It was thought that systemic aspergillosis was the cause of the new hemorrhagic infarct and enhancing lesions. A more conservative treatment course was followed.
Case 2
A 22-year-old Caucasian woman with Crohn's disease diagnosed at the age of 18 years, and a recent diagnosis of pure red cell aplasia, was treated with anti-thymocyte globulin at a dose of 2.4 g over a period of 4 days and prednisone for 14 days. She was then started on cyclosporin A orally at a dose of 200 mg three times daily. One day later, she developed a throbbing headache in the left temporoparietal area, which increased upon lying in the supine position. One week later, she developed an episode of leftsided numbness and weakness, which lasted for around 2 h. The following day, she developed similar symptoms on the right side as well as a partial deficit in the left visual field. Cyclosporin A level was 93 ng/ml. Neurologic examination revealed no abnormalities except for a congruous scotoma between 10 and 11 o'clock. Visual acuity was 20/20 in the right eye and 20/30 in the left eye. Her BP was 127/93 mm Hg. MRI of the brain showed scattered focal areas of increased T2 signal in the subcortical white matter of both posterior parietal lobes and right occipital lobe. The lesions were non-enhancing. MRA showed narrowing and irregularity of multiple vessels of the intracranial circulation with a beaded appearance, affecting mainly the basilar and right middle cerebral artery (Figure 3 ). Transcranial doppler ultrasound showed abnormally elevated blood flow velocities in several vessels, consistent with vasculitis/vasospasm ( Table 2) . Cyclosporin A was stopped. The next day, her headache improved markedly. She also had normal vision with no visual field defects. She was started on a higher dose of oral prednisone in order to treat a possible vasculitis that was slowly tapered over 6 weeks. MRA of the intracranial vasculature was repeated 1 month later and showed marked improvement of the intracranial arteries (Figure 4 ).
Discussion
The mechanism of cyclosporin A neurotoxicity is not well understood. Several hypotheses have been proposed. Bartynski et al 4 
suggested that cerebral vasculopathy in
Bone Marrow Transplantation patients with bone marrow transplants receiving cyclosporin A resulted from bone marrow transplant thrombotic microangiopathy, which could be diagnosed if the serum lactate dehydrogenase level was elevated in addition to an elevated schistocyte count. Their patients had multiple cerebral lesions corresponding to vascular watershed locations.
Another mechanism of cyclosporin A neurotoxicity may be similar to that caused by hypertensive encephalopathy and pre-eclampsia/eclampsia where cerebral vasospasm is a reaction to elevations in systemic BP, which exceeds the boundaries of cerebral autoregulation. 5 Truwit et al 6 proposed that cyclosporin A neurotoxicity occurs at lower BPs, suggesting focal vasoconstriction, which may be mediated by the release of endothelin. Evidence for vessel injury has been demonstrated by the finding of vessel wall thickening in medium-sized subarachnoid cerebral arteries in autopsy specimens. 7, 8 White matter changes are reversible in most cases. They are usually symmetric, non-enhancing, and located at anastomotic arterial border zones.
The lesions in cyclosporin A toxicity have been noted to resemble the brain lesions seen in pre-eclampsia. MRA findings in a patient with pre-eclampsia were described as Table 2 Mean intracranial blood flow velocities by transcranial ultrasound in case 2 performed on day 11 after starting cyclosporin A (cm/s) Basilar  siphon  siphon  artery   132  186  48  141  53  91  190  71  172 extensive arteriopathy similar to vasculitis or vasospasm. 9 To our knowledge, radiographic and ultrasonographic abnormalities in cerebral blood vessels associated with cyclosporin A toxicity have not previously been described. These abnormalities were reversible. The elevation of BP observed in case 1, may have contributed to cerebral vasospasm. In case 2, there was no elevation of BP from baseline. MRA findings resembled those found in the preeclamptic patient, where hypertension seems to be the primary trigger for vascular involvement. FK506 has been reported to cause neurotoxicity. It mainly manifests as white matter brain lesions. 10 The neurologic deterioration of case 1 fits the known cerebral effects of Aspergillus infection, including hemorrhagic infarctions and enhancing cortical lesions. An autopsy was not obtained. Although the exact pathophysiology of the cerebral lesions has not been elucidated, findings in our patients confirm the previously suspected vascular process ongoing during cyclosporin A toxicity.
